By Leroy Leo (Reuters) -Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a similar therapy…
Investing.com — K+S Group (ETR:SDFGn) on Thursday adjusted its financial guidance to the lower end of expectations, signaling a less optimistic outlook for 2024. The company’s EBITDA guidance…
TAIPEI (Reuters) – The head of Taiwan’s central bank said on Thursday that he doubted that U.S. President-elect Donald Trump’s new administration would penalise…
By Rae Wee SINGAPORE (Reuters) – Weak China markets dragged broader Asian shares lower on Thursday, while longer-dated U.S. bond yields rose alongside the…